Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04260256 · ClinicalTrials.gov registry record · Phase 2
A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
A Phase 2 study of Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit, sponsored by CellSight Technologies.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT04260256 is a Phase 2 study of Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit that is actively recruiting participants, run by CellSight Technologies. The registered enrollment target is 40 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT04260256, a Phase 2 study of Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit, is actively recruiting participants, sponsored by CellSight Technologies.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
In this study, patients with advanced solid tumors will undergo \[18F\]F AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.
Conditions Studied
Interventions
- DRUG [18F]F-AraG
Study Locations (2)
California
- Stanford University - Stanford
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04260256
The ClinicalTrials.gov registry entry for NCT04260256 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CellSight Technologies, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit appearing as the primary indexed condition, and to 1 intervention - of which [18F]F-AraG is the first listed.
NCT04260256 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Oregon.
Frequently Asked Questions
What is clinical trial NCT04260256 about?
NCT04260256 is a clinical study titled "A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors". In this study, patients with advanced solid tumors will undergo \[18F\]F AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.
What is the current status of trial NCT04260256?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2022-03-01. Estimated completion is 2026-11-30.
What conditions does trial NCT04260256 study?
This clinical trial studies the following conditions: Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit.
What interventions are being tested in trial NCT04260256?
The interventions under investigation include: [18F]F-AraG (DRUG).
Who is sponsoring clinical trial NCT04260256?
This trial is sponsored by CellSight Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04260256 being conducted?
This trial has 2 study locations across California, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.